国务院联防联控机制科研攻关组相关负责人表示，国家已批准将新冠疫苗紧急使用年龄范围扩大到3岁以上。

 

China is expected to administer COVID-19 vaccines² to at least 70 percent of the target population by the end of this year, an official from the National Health Commission confirmed, as the country continues to ramp³ up its inoculation⁴ drive to approve the emergency use of COVID-19 vaccines for those aged⁵ between 3 and 17 years old.

我国继续推进新冠疫苗接种工作，已批准将3-17岁人群纳入新冠疫苗紧急使用年龄范围。国家卫健委相关负责人表示，预计到今年年底前，我国将完成至少70%的目标人群接种。

 

Preliminary results from Phase I and II clinical trials showed the vaccine¹ could trigger immune response in three to 17 year-old participants, and most adverse⁶ reactions were mild.

Ⅰ/Ⅱ期临床试验初步结果显示，疫苗能够触发3到17岁接种者体内的免疫反应，多数不良反应轻微。

 

Following approval by relevant authorities, vaccination⁷ will be open to people in this age group based on the epidemic⁸ prevention and control situation .

经国家有关部门批准后，会根据疫情防控需要在这一人群中推动接种。

 

年龄最大接种者超过100岁

 

Over 763 million doses of COVID-19 vaccines had been administered across China as of Saturday, NHC figures showed.

国家卫健委发布的数据显示，截至6月5日，我国新冠疫苗接种已超过7.63亿剂次。

 

The oldest vaccine recipients⁹ in China's vaccination campaign, open to people aged over 18, are more than 100 years old.

目前我国新冠疫苗接种面向18岁以上人群，其中年龄最大的接种者超过100岁。

 

China is also making headway in creating nasal spray and inhaled¹⁰ COVID-19 vaccines as clinical trials of them are underway, and experts will study their safety and efficacy after completing the collection of relevant data.

我国在鼻喷雾式 / 吸入型新冠疫苗研发方面也有新进展，目前这种疫苗正在进行临床试验。相关数据收集完成后，专家将对其安全性和有效性展开研究。

点击收听单词发音